Primidone

Major

Primidone Cabozantinib Cabometyx Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Primidone Cabozantinib (Thyroid Cancer) Cabometyx Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Primidone Calcifediol Rayaldee Altered serum levels of calcifediol Details Primidone Capmatinib Tabrecta Decreased capmatinib exposure and reduction of antitumor activity Details Primidone Cetirizine Injection Aller-Tec Increased risk of CNS depression Details Primidone Cetirizine Ophthalmic Zerviate Increased risk of CNS depression Details Primidone Chloroquine Aralen® An increased risk of QT interval prolongation Details Primidone Clindamycin Injection ANTIROBE Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Primidone Clindamycin Topical C/T/S® Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Primidone Clindamycin Vaginal Cleocin Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Primidone Clopidogrel Plavix Reduced CYP2C19 substrate exposure and reduced efficacy of CYP2C19 substrate Details Primidone Cobimetinib Cotellic Decreased cobimetinib plasma concentrations Details Primidone Cyclophosphamide Cytoxan® Reduced cycloPHOSphamide exposure and a reduced efficacy of cycloPHOSphamide Details Primidone Cyclophosphamide Injection Cytoxan® Injection Reduced cycloPHOSphamide exposure and a reduced efficacy of cycloPHOSphamide Details Primidone Cyclosporine Injection Atopica Reduced cycloSPORINE exposure and reduced efficacy of cycloSPORINE Details Primidone Cyclosporine Ophthalmic Cequa Reduced cycloSPORINE exposure and reduced efficacy of cycloSPORINE Details Primidone Dabigatran Pradaxa® Reduced dabigatran exposure and increased risk of thrombotic events Details Primidone Dabigatran Etexilate Reduced dabigatran exposure and increased risk of thrombotic events Details Primidone Darolutamide Nubeqa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Primidone Dasatinib Phyrago An increased risk of QT interval prolongation, reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Primidone Deflazacort Emflaza Decreased exposure to active metabolite of deflazacort Details Primidone Degarelix Injection Firmagon An increased risk of QT interval prolongation Details Primidone Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Primidone Dexamethasone Injection Decadron Reduced dexAMETHasone exposure and reduced efficacy of dexAMETHasone Details Primidone Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Reduced dexAMETHasone exposure and reduced efficacy of dexAMETHasone Details Primidone Diazepam Nasal Spray Valtoco An increased risk of CNS and respiratory depression Details Primidone Diazepam Rectal Diastat An increased risk of CNS and respiratory depression Details Primidone Dihydroergotamine Injection DHE-45® Injection Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Primidone Dihydroergotamine Nasal Spray Migranal Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Primidone Diphenhydramine Injection Banophen An increased risk of CNS depression Details Primidone Diphenhydramine Topical Afterbite with Antihistamine An increased risk of CNS depression Details Primidone Disopyramide Norpace An increased risk of QT interval prolongation, reduced disopyramide exposure and reduced disopyramide efficacy Details Primidone Disulfiram Antabuse Increased PHENobarbital exposure and an increased risk of PHENobarbital-related adverse effects Details Primidone Docetaxel Beizray Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Primidone Docetaxel Injection Beizray Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Primidone Dofetilide Tikosyn An increased risk of QT interval prolongation, reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Primidone Dolasetron Anzemet An increased risk of QT interval prolongation Details Primidone Dolasetron Injection Anzemet An increased risk of QT interval prolongation Details Primidone Dolutegravir Juluca® (as a combination product containing dolutegravir, rilpivirine) Reduced dolutegravir exposure and reduced efficacy of dolutegravir Details Primidone Doxycycline Injection Acticlate Reduced doxycycline exposure and reduced efficacy of doxycycline Details